Fisher & Paykel share price slides hard following FY23 guidance update

The company reaffirmed its posture to the market today.

| More on:
Man going down a red arrow, symbolising a sliding share price.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Key points

  • Fisher & Paykel posted its guidance for the first half of FY23 
  • Investors have sold off shares en masse following the update 
  • In the past 12 months, the Fisher & Paykel share price is down 44% 

The Fisher & Paykel Healthcare Corp Ltd (ASX: FPH) share price is struggling from the open on Friday following a company update.

At the time of writing, the Fisher & Paykel share price is trading 6% down at $17.98 after it announced its FY23 guidance.

Fisher & Paykel expects slow down in FY23

Detailing its forecasts for the coming 12 months, the healthcare giant said that it anticipates revenue of $670 million and net profit after tax (NPAT) of $85–$95 million.

This signifies an increase in revenue compared to 1H FY20's $570.9 million yet a decline in revenue compared to the prior comparable period, being 1H FY22 at $900 million.

CEO Lewis Gradon said the company had "sold approximately ten years' worth of hardware in two years" creating a high comparison in FY22 as well.

"This does not change the fundamentals of our business or our strategy," he added.

"Our Hospital sales teams are still focused on changing clinical practice and helping ensure the hardware our customers have purchased is used to benefit a broader range of patients requiring respiratory support."

Gross margin for the first half is also expected to land at 60% – 500 basis points below the company's long-term target of 65%.

Part of the contraction in gross profit is due to a shift in sales towards the lower margin consumables segment.

However, despite challenges, it expects that H2 FY23 revenue will be higher than the first half as hospitalisation rates normalize.

"The company is now targeting constant currency operating expense growth of approximately 10%
for the year," it added.

Never before in our history have we changed clinical practice with such a significant advantage.
Our customers already have our hardware, they already have clinical experience with its use, and
they already have access to a huge amount of clinical evidence. This gives us confidence that we
can continue to build on our proven 50-year track record and reach more patients with our
respiratory therapies.

In the past 12 months, the Fisher & Paykel share price is down 44%, and down 41% this year to date.

Motley Fool contributor Zach Bristow has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

ecommerce asx shares represented by santa doing online shopping on laptop
Healthcare Shares

Looking for ideas before Christmas? These 2 ASX shares stand out to me

Two ASX shares at opposite ends of the market are catching my attention as the year draws to a close.

Read more »

A doctor or medical expert in COVID protection adjusts her glasses, indicating growth or strong share price movement in ASX medical, biotech and health companies
Opinions

Forget CSL shares, I'd buy this booming biotech stock instead

This ASX biotech stock has caught my eye this year.

Read more »

A medical researcher rests his forehead on his fist with a dejected look on his face while sitting behind a scientific microscope with another researcher's hand on his shoulder as if giving comfort.
Healthcare Shares

Telix Pharmaceuticals shares crash 58% from their peak: Buying opportunity or time to sell up?

The biopharmaceutical company's shares are tipped to soar next year.

Read more »

A male ASX investor sits cross-legged with a laptop computer in his lap with a slightly crazed, happy, excited look on his face while next to him a graphic of a rocket shoots upwards with graphics of stars scattered around it
Healthcare Shares

Up 10x since July, could this hot ASX stock be the next Droneshield?

Investors chase asymmetric upside and 4DMedical is one of the ASX's hottest stocks right now.

Read more »

A couple smile as they look at a pregnancy test.
Healthcare Shares

Is Medibank stock a buy for its 5.5% dividend yield?

This business is providing investors with very healthy dividends.

Read more »

A doctor shrugs and holds his hands out.
Healthcare Shares

Down 36% in 2025, should you buy CSL shares today?

A leading investment expert offers his outlook for CSL’s beaten-down share price.

Read more »

Three guys in shirts and ties give the thumbs down.
Healthcare Shares

Why did Macquarie just downgrade CSL shares?

The broker has taken an axe to its valuation of this biotech giant.

Read more »

Scientists working in the laboratory and examining results.
Healthcare Shares

Which drug company could pile on almost 30% in gains according to RBC Capital?

This drug company has plenty of irons in the fire, RBC Capital Markets says.

Read more »